Introduction
Primary hyperoxaluria is a general term for at least 2 rare recessive genetic disorders of metabolism (Archer et al., 1957; Williams and Smith, 1968) characterized by increased endogenous synthesis of oxalic acid, recurrent nephrolithiasis, extra-renal oxalate deposits (oxalosis), progressive nephrocalcinosis and renal failure with eventual terminal uraemia.
In Type I primary hyperoxaluria, the patients lack the enzyme 2-oxoglutarate glyoxylate carboligase, and the urinary excretion of glycollate and glyoxylate as well as oxalate are increased (Williams and Smith, 1968) . In Type II primary hyperoxaluria, the metabolic lesion is a lack of D-glycerate dehydrogenase, the excretion of L-glycerate is increased but glycollate and glyoxylate excretion are normal (Williams and Smith, 1968) . Only 4 patients with Type II primary hyperoxaluria are known.
The management of terminal renal failure in primary hyperoxaluric patients by dialysis and/or transplantation has been the subject of a number of reports over the past 10 years. Peritoneal dialysis does not seem sufficiently efficient to prevent ischaemic lesions, secondary to diffuse infiltration of arteries by oxalate crystals developing (Arbus and Sniderman, 1974; Klauwers, Wolff and Cohn, 1969; Zarembski, Rosen and Hodgkinson, 1969) . Results achieved with haemodialysis are better, but nevertheless numerous complications arise and the average duration of survival of patients with primary hyperoxaluria appears to be significantly shorter than for the other groups of patients treated with intermittent haemodialysis (Jacobs et al., 1975a; Boquist et al., 1973; Blackburn et al., 1975; Jacobs et al., 1975b; Toussaint et al., 1976 One month later, a live donor renal transplant was carried out, the patient's mother being the donor. There was an HLA haplotype in common. There was immediate, good postoperative function with a diuresis of 36 litres in the first 24 hr, containing 7680 ,umol of oxalic acid. The standard immunosuppressives, azathioprine and prednisolone, were given and rejection episodes on the 7th, 11th, 49th and 68th postoperative days responded readily to high-dose intravenous methylprednisolone. In addition, pyridoxine, initially 50 mg 4 times/day and after one month 200 mg 4 times/day, was given.
In Table 1 the results of 4 measurements which have been used to assess renal function and the efficacy of treatment are shown. From these it will be seen that one week before transplantation the urinary oxalate, because of the very low renal clearance, was only 270 ,umol/24 hr; the plasma oxalate and the exchangeable oxalate pool (both measured using a method described by the present authors (Constable et al., 1979) were 160 [±mol/l and 4429 t±mol respectively, these are the highest levels ever recorded at this hospital. After the transplant, the plasma oxalate and the exchangeable oxalate pool showed a very large reduction although they remain elevated beyond the normal range by a factor of 2, even allowing for the reduced creatinine clearance (personal observation); the urinary oxalate has been less than 1100 ,mol since the operation and with improved communication, allowing better dietary instructions, resulting in the avoidance of oxalate-rich foods, a reduction almost to normal levels has recently been achieved; the creatinine clearance is now quite stable at about 60 ml/min.
A renal biopsy ( Fig. 1 ) carried out 9 months post-transplant, shows some rejection changes and just a few intratubular birefringent calcium oxalate crystals. A plain X-ray of the abdomen at 20 months postoperatively ( Fig. 2) shows the patient's 2 original kidneys in situ with bilateral nephrocalcinosis and nephrolithiasis but no suggestion of nephrocalcinosis or calculi in the transplanted kidney.
In the 29 months since the transplant, the patient has remained well with no evidence of extra-renal oxalate deposits in the retina, cardiac conducting system or peripheral arteries.
Discussion
Since the transplant, pyridoxine therapy has been of importance to this patient in maintaining his urinary oxalate, plasma oxalate and exchangeable oxalate pool at levels which avoid the severe renal, vascular, ocular and cardio-conductive lesions associated with primary hyperoxaluria. Pre-transplant maintenance haemodialysis and pre-transplant pyridoxine therapy may also have reduced the oxalate load on the allograft but it proved capable of excreting 7680 ,umol of oxalate in the first 24 hr postoperatively with only minimal intrarenal calcium Many drugs have been tested in an effort to reduce endogenous oxalate formation in primary hyperoxaluric patients, only pyridoxine has been shown to be consistently effective in a large proportion. In initial animal studies, pyridoxine deficiency was found to cause hyperoxaluria and oxalate nephrocalcinosis (Gershoff et al., 1959a) . Subsequent experimental pyridoxine deficiency in human subjects increased oxalate excretion and studies have shown that pyridoxine reduces urinary oxalate in mentally subnormal children (Gershoff, Mayer and Kulczycki, 1959b) and normal adults (McLaurin et al., 1961) . A definitive reduction of the urinary oxalic acid in patients with primary hyperoxaluria given large doses of pyridoxine was shown by Smith and Williams (1967) and Gibbs and Watts (1970 (Jacobs et al., 1975b; Wilson, 1975) . Therefore only 16 transplants in 13 patients with well documented primary hyperoxaluria can be reviewed.
Some details of these cases are summarized in Wenzl, 1974) . Jacobsen and Mosbaek's patient was maintained on peritoneal dialysis for several months before transplantation, the graft never functioned satisfactorily and after 2 weeks of oliguria, during which only two haemodialyses were given, a creatinine clearance of 7 ml/min with a urinary excretion of 1875 ml/24 hr, was achieved. Pyridoxine in a dosage of only 100 mg daily was given (Jacobsen and Mosbaek, 1974) . This kidney would appear to have been unable to cope with the massive oxalic acid load which must have accumulated during the several months of maintenance peritoneal dialysis before transplantation and the 2 weeks' oliguria after the transplant, also pyridoxine 100 mg daily, would not be sufficient to reduce endogenous oxalic acid production.
The death of the patient reported by Toussaint et al. (1976) group.bmj.com on May 2, 2017 -Published by http://pmj.bmj.com/ Downloaded from crystal deposition. It would also seem wise to instruct patients to maintain a high fluid intake and avoid oxalate-rich foods. Living related donor kidneys may be preferable for transplantation as the degree of tubular necrosis is likely to be less than in cadaveric kidneys and there is no evidence that the heterozygous kidneys are more susceptible to oxalosis than normal. On the other hand, this does not seem to be too important as the 2 other successful renal transplants in primary hyperoxaluric patients have been carried out from cadaveric donors.
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